Abstract
A long time ago, metastatic brain tumors were often not treated and patients were only given palliative care. In the past decade, researchers selected those with single or 1-3 metastases for more aggressive treatments like surgical resection, and/or stereotactic radiosurgery (SRS), since the addition of whole brain radiotherapy (WBRT) did not increase overall survival for the vast majority of patients. Different studies demonstrated significantly less cognitive deterioration in 0-52% patients after SRS versus 85-94% after WBRT at 6 months. WBRT is the treatment of choice for leptomeningeal metastases. WBRT can lower the risk for further brain metastases, particularly in tumors of fast brain metastasis velocity, i.e. quickly relapsing, often seen in melanoma or small cell lung carcinoma. Important relevant literature is quoted to clarify the clinical controversies at point of care in this review. Synchronous primary lung cancer and brain metastasis represent a special situation whereby the oncologist should exercise discretion for curative treatments, with reported 5-year survival rates of 7.6%-34.6%. Recent research suggests that those patients with Karnofsky performance status less than 70, not capable of caring for themselves, are less likely to derive benefit from aggressive treatments. Among patients with brain metastases from non-small cell lung cancer (NSCLC), the QUARTZ trial (Quality of Life after Radiotherapy for Brain Metastases) helps the oncologist to decide when not to treat, depending on the performance status and other factors.
Keywords: Brain tumors, palliative care, metastases, surgery, stereotactic radiosurgery, whole brain radiotherapy.
Graphical Abstract
[1]
Ellis TL, Neal MT, Chan MD. The role of surgery, radiosurgery and whole brain radiation therapy in the management of patients with metastatic brain tumors. Int J Surg Oncol 2012; 2012 952345
[2]
Bragstad S, Flatebø M, Natvig GK, et al. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study. J Neurosurg 2017; 18: 1-13.
[3]
Kirkpatrick JP, Soltys SG, Lo SS, et al. The radiosurgery fractionation quandary: single fraction or hypofractionation? Neuro-oncol 2017; 19(Suppl. 2): ii38-49.
[4]
Pollock BE, Link MJ, Stafford SL, et al. The risk of radiation-induced tumors or malignant transformation after single-fraction intracranial radiosurgery: Results based on a 25-year experience. Int J Radiat Oncol Biol Phys 2017; 97(5): 919-23.
[5]
Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37(4): 745-51.
[6]
Sanghavi SN, Miranpuri SS, Chappell R, et al. Radiosurgery for patients with brain metastases: A multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys 2001; 51(2): 426-34.
[7]
Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008; 70(2): 510-4.
[8]
Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010; 77(3): 655-61.
[9]
Hirshman BR, Wilson BR, Ali MA, et al. Cumulative intracranial tumor volume augments the prognostic value of Diagnosis-Specific Graded Prognostic Assessment Model for survival in patients with melanoma cerebral metastases. Neurosurgery 2018; 83(2): 237-44.
[10]
Sperduto PW, Jiang W, Brown PD, et al. Estimating survival in melanoma patients with brain metastases: An update of the Graded Prognostic Assessment for Melanoma using molecular markers (Melanoma-molGPA). Int J Radiat Oncol Biol Phys 2017; 99(4): 812-6.
[11]
Tsao MN, Rades D, Wirth A, et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2012; 2(3): 210-25.
[12]
Lowell D, Tatter SB, Bourland JD, et al. Toxicity of gamma knife radiosurgery in the treatment of intracranial tumors in patients with collagen vascular diseases or multiple sclerosis. Int J Radiat Oncol Biol Phys 2011; 81(4): e519-24.
[13]
Frytak S, Shaw JN, O’Neill BP, et al. Leukoencephalopathy in small cell lung cancer patients receiving prophylactic cranial irradiation. Am J Clin Oncol 1989; 12(1): 27-33.
[14]
Li M, Caeyenberghs K. Longitudinal assessment of chemotherapy-induced changes in brain and cognitive functioning: A systematic review. Neurosci Biobehav Rev 2018; 7634(17): 30733-9.
[15]
Ellis TL, Neal MT, Chan MD. The role of surgery, radiosurgery and whole brain radiation therapy in the management of patients with metastatic brain tumors. Int J Surg Oncol 2012; 2012 952345
[16]
Ruge MI, Kocher M, Maarouf M, et al. Comparison of stereotactic brachytherapy (125 iodine seeds) with stereotactic radiosurgery (LINAC) for the treatment of singular cerebral metastases. Strahlenther Onkol 2011; 187(1): 7-14.
[17]
Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole brain irradiation: A randomised controlled trial. Lancet Oncol 2009; 10(11): 1037-44.
[18]
Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29(2): 134-41.
[19]
Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: Quality-of-life results. J Clin Oncol 2013; 31: 65-72.
[20]
Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: A Randomized Clinical Trial. JAMA 2016; 316(4): 401-9.
[21]
Habets EJ, Dirven L, Wiggenraad RG, et al. Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases: A prospective study. Neuro-oncol 2016; 18: 435-44.
[22]
McTyre ER, Johnson AG, Ruiz J, et al. Predictors of neurologic and nonneurologic death in patients with brain metastasis initially treated with upfront stereotactic radiosurgery without whole brain radiation therapy. Neuro-oncol 2017; 19(4): 558-66.
[23]
Johnson AG, Ruiz J, Hughes R, et al. Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget 2015; 6(22): 18945-55.
[24]
Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol 2014; 15(4): 387-95.
[25]
Epstein BE, Scott CB, Sause WT, et al. Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28. Cancer 1993; 71(4): 1362-7.
[26]
Murray KJ, Scott C, Greenberg HM, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 1997; 39(3): 571-4.
[27]
Rades D, Veninga T, Janssen S, Schild SE. Outcomes after whole brain radiotherapy for brain metastases with 5×4 Gy: Importance of overall treatment time. Anticancer Res 2016; 36(9): 4941-5.
[28]
Gondi V, Tome WA, Marsh J, et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole brain radiotherapy: Safety profile for RTOG 0933. Radiother Oncol 2010; 95(3): 327-31.
[29]
Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole brain radiotherapy for brain metastases (RTOG 0933): A phase II multi-institutional trial. J Clin Oncol 2014; 32: 3810-6.
[30]
Okoukoni C, McTyre ER, Ayala Peacock DN, et al. Hippocampal dose volume histogram predicts Hopkins Verbal Learning Test scores after brain irradiation. Adv Radiat Oncol 2017; 2(4): 624-9.
[31]
Tsai PF, Yang CC, Chuang CC, et al. Hippocampal dosimetry correlates with the change in neurocognitive function after hippocampal sparing during whole brain radiotherapy: A prospective study. Radiat Oncol 2015; 10: 253.
[32]
Brown PD, Pugh S, Laack NN, et al. Radiation Therapy Oncology Group (RTOG). Memantine for the prevention of cognitive dysfunction in patients receiving whole brain radiotherapy: A randomized, double-blind, placebo-controlled trial. Neuro-oncol 2013; 15(10): 1429-37.
[33]
Slade AN, Stanic S. The impact of RTOG 0614 and RTOG 0933 trials in routine clinical practice: The US Survey of Utilization of Memantine and IMRT planning for hippocampus sparing in patients receiving whole brain radiotherapy for brain metastases. Contemp Clin Trials 2016; 47: 74-7.
[34]
Muacevic A, Wowra B, Siefert A, Tonn JC, Steiger HJ, Kreth FW. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: A randomized controlled multicentre phase III trial. J Neurooncol 2008; 87(3): 299-307.
[35]
Mehta M, Noyes W, Craig B, et al. A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases. Int J Radiat Oncol Biol Phys 1997; 39(2): 445-54.
[36]
Marks LB, Ten Haken RK, Martel MK. Guest editor’s introduction to QUANTEC: A users guide. Int J Radiat Oncol Biol Phys 2010; 76(3)(Suppl.): S1-2.
[37]
Kirkpatrick JP, Marks LB, Mayo CS, Lawrence YR, Bhandare N, Ryu S. Estimating normal tissue toxicity in radiosurgery of the CNS: Application and limitations of QUANTEC. J Radiosurg SBRT 2011; 1(2): 95-107.
[38]
Wiggenraad R, Verbeek-de Kanter A, Kal HB, Taphoorn M, Vissers T, Struikmans H. Dose-effect relation in stereotactic radiotherapy for brain metastases. A systematic review. Radiother Oncol 2011; 98(3): 292-7.
[39]
Rades D, Huttenlocher S, Gebauer N, et al. Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. Anticancer Res 2015; 35(6): 3571-4.
[40]
Levy A, Saiag P, Chargari C, Assouline A. Focal 3D conformal high-dose hypofractionated radiotherapy for brain metastases. Melanoma Res 2012; 22(5): 406-9.
[41]
Assouline A, Levy A, Chargari C, Lamproglou I, Mazeron JJ, Krzisch C. Whole brain radiotherapy: Prognostic factors and results of a radiation boost delivered through a conventional linear accelerator. Radiother Oncol 2011; 99(2): 214-7.
[42]
Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 2002; 53(3): 519-26.
[43]
Raizer J. Radiosurgery and whole brain radiation therapy for brain metastases: Either or both as the optimal treatment. JAMA 2006; 295(21): 2535-6.
[44]
Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): A multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18(8): 1049-60.
[45]
Ayala-Peacock DN, Peiffer AM, Lucas JT, et al. A nomogram for predicting distant brain failure in patients treated with gamma knife stereotactic radiosurgery without whole brain radiotherapy. Neuro-oncol 2014; 16(9): 1283-8.
[46]
Farris M, McTyre ER, Cramer CK, et al. Brain metastasis velocity: A novel prognostic metric predictive of overall survival and freedom from whole brain radiation therapy after distant brain failure following upfront radiosurgery alone. Int J Radiat Oncol Biol Phys 2017; 98(1): 131-41.
[47]
McTyre E, Helis CA, Farris M, et al. Emerging indications for fractionated Gamma Knife radiosurgery. Neurosurgery 2017; 80(2): 210-6.
[48]
Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363(9422): 1665-72.
[49]
Gorovets D, Ayala-Peacock D, Tybor DJ, et al. Multi-institutional nomogram predicting survival free from salvage whole brain radiation after radiosurgery in patients with brain metastases. Int J Radiat Oncol Biol Phys 2017; 97(2): 246-53.
[50]
Sperduto PW, Shanley R, Luo X, et al. Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA). Int J Radiat Oncol Biol Phys 2014; 90(3): 526-31.
[51]
Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18(8): 1040-8.
[52]
Kępka L, Tyc-Szczepaniak D, Bujko K, et al. Stereotactic radiotherapy of the tumor bed compared to whole brain radiotherapy after surgery of single brain metastasis: Results from a randomized trial. Radiother Oncol 2016; 121(2): 217-24.
[53]
Jensen CA, Chan MD, McCoy TP, et al. Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis. J Neurosurg 2011; 114(6): 1585-91.
[54]
Minniti G, Esposito V, Clarke E, et al. Multidose stereotactic radiosurgery (9 Gy × 3) of the postoperative resection cavity for treatment of large brain metastases. Int J Radiat Oncol Biol Phys 2013; 86(4): 623-9.
[55]
Hartford AC, Paravati AJ, Spire WJ, et al. Postoperative stereotactic radiosurgery without whole brain radiation therapy for brain metastases: Potential role of preoperative tumor size. Int J Radiat Oncol Biol Phys 2013; 85(3): 650-5.
[56]
Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322(8): 494-500.
[57]
Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 1998; 280(17): 1485-9.
[58]
Zhu H, Bi Y, Han A, et al. Risk factors for brain metastases in completely resected small cell lung cancer: A retrospective study to identify patients most likely to benefit from prophylactic cranial irradiation. Radiat Oncol 2014; 9: 216.
[59]
Zhu H, Guo H, Shi F, et al. Prophylactic cranial irradiation improved the overall survival of patients with surgically resected small cell lung cancer, but not for stage I disease. Lung Cancer 2014; 86(3): 334-8.
[60]
Bloom BC, Augustyn A, Sepesi B, et al. Prophylactic cranial irradiation following surgical resection of early-stage small-cell lung cancer: A review of the literature. Front Oncol 2017; 7: 228.
[61]
Aoyama H, Tago M, Shirato H. Japanese Radiation Oncology Study Group 99-1. (JROSG 99-1) Investigators. Stereotactic radiosurgery with or without whole brain radiotherapy for brain metastases: Secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol 2015; 1(4): 457-64.
[62]
Rades D, Huttenlocher S, Dahlke M, et al. Comparison of two dose levels of stereotactic radiosurgery for 1-3 brain metastases from non-small cell lung cancer. Anticancer Res 2014; 34(12): 7309-13.
[63]
Antuña AR, Vega MA, Sanchez CR, Fernandez VM. Brain metastases of non-small cell lung cancer: prognostic factors in patients with surgical resection. J Neurol Surg A Cent Eur Neurosurg 2017; 32(2): 129-36.
[64]
De Pas TM, de Braud F, Catalano G, et al. Oligometastatic non-small cell lung cancer: A multidisciplinary approach in the positron emission tomographic scan era. Ann Thorac Surg 2007; 83(1): 231-4.
[65]
Toffart AC, Duruisseaux M, Brichon PY, et al. Operation and chemotherapy: Prognostic factors for lung cancer with one synchronous metastasis. Ann Thorac Surg 2018; 105(3): 957-65.
[66]
Bernhardt D, Adeberg S, Bozorgmehr F, et al. Outcome and prognostic factors in single brain metastases from small-cell lung cancer. Strahlenther Onkol 2018; 194(2): 98-106.
[67]
Hu C, Chang EL, Hassenbusch SJ 3rd, et al. Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. Cancer 2006; 106(9): 1998-2004.
[68]
Flannery TW, Suntharalingam M, Regine WF, et al. Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys 2008; 72(1): 19-23.
[69]
Yuksel C, Bozkurt M, Yenigun BM, et al. The outcome of bifocal surgical resection in non-small cell lung cancer with synchronous brain metastases: Results of a single center retrospective study. Thorac Cardiovasc Surg 2014; 62(7): 605-11.
[70]
Lo CK, Yu CH, Ma CC, Ko KM, Leung SC. Surgical management of primary non-small-cell carcinoma of lung with synchronous solitary brain metastasis: Local experience. Hong Kong Med J 2010; 16(3): 186-91.
[71]
Burt M, Wronski M, Arbit E, Galicich JH. Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. J Thorac Cardiovasc Surg 1992; 103(3): 399-410.
[72]
Griffioen GH, Toguri D, Dahele M, et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): Patient outcomes and prognostic factors. Lung Cancer 2013; 82(1): 95-102.
[73]
Parlak C, Mertsoylu H, Güler OC, Onal C, Topkan E. Definitive chemoradiation therapy following surgical resection or radiosurgery plus whole brain radiation therapy in non-small cell lung cancer patients with synchronous solitary brain metastasis: A curative approach. Int J Radiat Oncol Biol Phys 2014; 88(4): 885-91.
[74]
Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung. In: Amin MB, Ed. AJCC cancer staging manual. 8th ed. Springer: New York. 2017; pp. 431-56.
[75]
Nieder C, Hintz M, Oehlke O, Bilger A, Grosu AL. The TNM 8 M1b and M1c classification for non-small cell lung cancer in a cohort of patients with brain metastases. Clin Transl Oncol 2017; b19(9): 1141-6.
[76]
Mussi A, Lucchi M, Rossi G, Parenti G, Angeletti CA. Pulmonary carcinoma and solitary intracranial metastasis: Results of the combined surgical treatment. Minerva Chir 1995; 50(10): 849-58.
[77]
Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): Results from a phase 3, non-inferiority, randomised trial. Lancet 2016; 388(10055): 2004-14.
[78]
EuroQol G. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
[79]
Sperduto PW, Wang M, Robins HI, et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 2013; 85(5): 1312-8.
[81]
Hida T, Nokihara H, Kondo M, et al. Alectinib versus Crizotinib in patients with ALK-positive non-small-cell cancer (J-ALEX). Lancet 2017; 390(10089): 29.
[82]
Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998; 88(1): 11-20.
[83]
American Society of Clinical Oncology Available from:. https:// am.asco.org/combined-checkpoint-inhibition-ushers-newera-cns-therapy-melanoma
[84]
Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): A multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 2017; 18(7): 863-73.
[85]
An Y, Jiang W, Kim BYS, et al. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 2017; 125(1): 80-8.
[86]
Neal MT, Chan MD, Lucas JT Jr, et al. Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg 2014; 82(6): 1250-5.
[87]
Manon R, O’Neill A, Knisely J, et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: An Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol 2005; 23: 8870-6.
[88]
Dyer MA, Arvold ND, Chen YH, et al. The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol 2014; 9: 143.
[89]
Fogarty G, Morton RL, Vardy J, et al. Whole brain RT after local treatment of brain metastases in melanomapatients–a randomised phase III trial. BMC Cancer 2011; 11: 142.
[90]
Huttenlocher S, Sehmisch L, Schild SE, et al. Identifying melanoma patients with 1-3 brain metastases who may benefit from whole brain irradiation in addition to radiosurgery. Anticancer Res 2014; 34(10): 5589-92.
[91]
Rades D, Sehmisch L, Bajrovic A, et al. Comparison of 20×2 Gy and 12×3 Gy for Whole brain Irradiation of Multiple Brain Metastases from Malignant Melanoma. In Vivo 2016; 30(6): 917-9.
[92]
Rades D, Sehmisch L, Huttenlocher S, et al. Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: Impact of dose on treatment outcomes. Anticancer Res 2014; 34(9): 5079-82.
[93]
Hong AM, Suo C, Valenzuela M, et al. Low incidence of melanoma brain metastasis in the hippocampus. Radiother Oncol 2014; 111(1): 59-62.
[94]
Leone JP, Leone BA. Breast cancer brain metastases: The last frontier. Exp Hematol Oncol 2015; 4: 33.
[95]
Vern-Gross TZ, Lawrence JA, Case LD, et al. Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery. J Neurooncol 2012; 110(3): 381-8.
[96]
Niwinska A, Murawska M, Pogoda K. Breast cancer brain metastases; difference in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole brain radiotherapy (WBRT). Ann Oncol 2010; 21(5): 942-8.
[97]
McKee MJ, Keith K, Deal AM, et al. A multidisciplinary breast cancer brain metastases clinic: The University of North Carolina Experience. Oncologist 2016; 21(1): 16-20.
[98]
Dziggel L, Dahlke M, Janssen S, et al. Predicting the risk of new cerebral lesions after stereotactic radiosurgery (SRS) for brain metastases from breast cancer. Anticancer Res 2015; 35(12): 6793-7.
[99]
Rades D, Huttenlocher S, Rudat V, et al. Radiosurgery with 20 Gy provides better local control of 1-3 brain metastases from breast cancer than with lower doses. Anticancer Res 2015; 35(1): 333-6.
[100]
ASTRO. Targeting Cancer Care Available from: https://www. astro.org/Clinical-Practice-Statements.aspx
Call for Papers in Thematic Issues
02 October, 2024
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Cancer Drug Targets
Combinatorial Chemistry & High Throughput Screening
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Current Drug Delivery
Related Books
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Advanced Pharmacy
Plant-derived Hepatoprotective Drugs
Cancer Genes
The Role of Chromenes in Drug Discovery and Development
Article Metrics
31